Skip to content

Cytokinetics

US · CYTK #1564 by market cap Listed 1970
50.78 -0.68 -1.32%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 5 in the most recent period (2026/Q3).
  • Total institutional ownership rose 0.9 percentage points.

Ownership vs. money flow

Diverging

Institutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
118.23% +0.94pp
Institutions
578 +5
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund86.42%
Hedge Fund18.60%
Public Company5.41%
Private Company2.94%
VC/PE Fund2.68%
Government Pension Fund0.94%
Sovereign Wealth Fund0.73%
Insurance Company0.42%
Individual/Insider0.34%

Top holders as of 2026-09-30

BlackRock 15.10% · 21.04M sh
T. Rowe Price Group, Inc. 14.84% · 20.68M sh
State Street Global Advisors 5.13% · 7.14M sh
Wellington Management Group 4.98% · 6.93M sh
Vanguard Portfolio Management, LLC 4.88% · 6.80M sh
Vanguard Capital Management, LLC 4.50% · 6.27M sh
FMR 3.61% · 5.01M sh
Avoro Capital Advisors LLC 3.59% · 5.00M sh
Bank of America Corporation 3.18% · 4.43M sh
Geode Capital Management, LLC 2.70% · 3.77M sh
Capital Research 2.06% · 2.86M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 16 buys · 34 sells

NameRoleStake
Robert Blum Chief Executive Officer 0.09%
Fady Malik Officer 0.07%
John Henderson Independent Chairperson 0.06%
Wendell Wierenga Independent Director 0.03%
Nancy Wysenski Independent Director 0.02%
Muna Bhanji Independent Director 0.02%
Robert Harrington Independent Director 0.02%
Sung Lee EVP & CFO 0.01%
B. Parshall Independent Director 0.01%
Edward Kaye Independent Director 0.01%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-08 B. Parshall Independent Director Open Market Disposition -5,000 $54.17–55.26
2026-11-02 Fady Malik Officer Derivative Exercise and Sale -3,500 $7.80–62.93
2026-11-01 Robert Blum Chief Executive Officer Derivative Exercise and Sale -7,500 $10.60–62.81
2026-10-19 Fady Malik Officer Derivative Exercise and Sale -3,500 $7.80–64.01
2026-10-15 Wendell Wierenga Independent Director Other Acquisition +97 $63.92
2026-10-15 Nancy Wysenski Independent Director Other Acquisition +97 $63.92
2026-10-15 John Henderson Independent Chairperson Other Acquisition +352 $63.92
2026-10-15 James Daly Independent Director Other Acquisition +195 $63.92
2026-10-15 Robert Harrington Independent Director Other Acquisition +195 $63.92
2026-10-15 Edward Kaye Independent Director Other Acquisition +195 $63.92
2026-10-11 Robert Blum Chief Executive Officer Derivative Exercise and Sale -7,500 $10.60–62.88
2026-10-05 Fady Malik Officer Derivative Exercise and Sale -3,500 $7.80–61.38
2026-09-27 Robert Blum Chief Executive Officer Derivative Exercise and Sale -7,500 $10.60–65.46
2026-09-21 Fady Malik Officer Derivative Exercise and Sale -3,500 $7.80–68.29
2026-09-14 Robert Blum Chief Executive Officer Open Market Disposition -97,926 $69.33
2026-09-14 Robert Landry Independent Director Open Market Disposition -1,000 $72.13
2026-09-13 Robert Blum Chief Executive Officer Other Acquisition +97,926 --
2026-09-13 Robert Blum Chief Executive Officer Other Disposition -99,276 --
2026-09-13 Robert Blum Chief Executive Officer Derivative Exercise and Sale -7,500 $10.60–73.44
2026-09-10 Robert Landry Independent Director Open Market Disposition -1,000 $74.66

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:43 · For reference only, not investment advice and not tailored to your situation.

Cytokinetics discussion 0 comments

Add a comment